key: cord-0749134-owiisw3y
authors: Lartey, Nathaniel L.; Valle‐Reyes, Salvador; Vargas‐Robles, Hilda; Jiménez‐Camacho, Karina E.; Guerrero‐Fonseca, Idaira M.; Castellanos‐Martínez, Ramón; Montoya‐García, Armando; García‐Cordero, Julio; Cedillo‐Barrón, Leticia; Nava, Porfirio; Filisola‐Villaseñor, Jessica G.; Roa‐Velázquez, Daniela; Zavala‐Vargas, Dan I; Morales‐Ríos, Edgar; Salinas‐Lara, Citlaltepetl; Vadillo, Eduardo; Schnoor, Michael
title: ADAM17/MMP inhibition prevents neutrophilia and lung injury in a mouse model of COVID‐19
date: 2021-11-26
journal: J Leukoc Biol
DOI: 10.1002/jlb.3cova0421-195rr
sha: f2a291538cab5579ce4f84966af6bf5a0f521880
doc_id: 749134
cord_uid: owiisw3y

Severe coronavirus disease 2019 (COVID‐19) is characterized by lung injury, cytokine storm, and increased neutrophil‐to‐lymphocyte ratio (NLR). Current therapies focus on reducing viral replication and inflammatory responses, but no specific treatment exists to prevent the development of severe COVID‐19 in infected individuals. Angiotensin‐converting enzyme‐2 (ACE2) is the receptor for SARS‐CoV‐2, the virus causing COVID‐19, but it is also critical for maintaining the correct functionality of lung epithelium and endothelium. Coronaviruses induce activation of a disintegrin and metalloprotease 17 (ADAM17) and shedding of ACE2 from the cell surface resulting in exacerbated inflammatory responses. Thus, we hypothesized that ADAM17 inhibition ameliorates COVID‐19‐related lung inflammation. We employed a preclinical mouse model using intratracheal instillation of a combination of polyinosinic:polycytidylic acid (poly(I:C)) and the receptor‐binding domain of the SARS‐CoV‐2 spike protein (RBD‐S) to mimic lung damage associated with COVID‐19. Histologic analysis of inflamed mice confirmed the expected signs of lung injury including edema, fibrosis, vascular congestion, and leukocyte infiltration. Moreover, inflamed mice also showed an increased NLR as observed in critically ill COVID‐19 patients. Administration of the ADAM17/MMP inhibitors apratastat and TMI‐1 significantly improved lung histology and prevented leukocyte infiltration. Reduced leukocyte recruitment could be explained by reduced production of proinflammatory cytokines and lower levels of the endothelial adhesion molecules ICAM‐1 and VCAM‐1. Additionally, the NLR was significantly reduced by ADAM17/MMP inhibition. Thus, we propose inhibition of ADAM17/MMP as a novel promising treatment strategy in SARS‐CoV‐2‐infected individuals to prevent the progression toward severe COVID‐19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent that causes coronavirus disease 2019 (COVID- 19) , which can lead to lung failure in susceptible individuals. 1 This virus has infected 226,013,637 people and caused 4,653,053 deaths worldwide (Source: https://coronavirus.jhu.edu/map.html; November 15, 2021) . SARS and severe COVID-19 are characterized by pulmonary edema, fibrosis, activation of the coagulation cascade, hypoxia, and hypercapnia (increased levels of CO 2 in the blood). 2 Moreover, severe COVID-19 is characterized by neutrophilia (increased neutrophil numbers in the blood) and lymphopenia (reduced lymphocyte numbers in the blood) and thus increased neutrophil-to-lymphocyte ratio (NLR). 3, 4 Excessive neutrophil presence and recruitment to the lung and transmigration into the alveolar luminal space contribute to lung injury as neutrophils release proteases, reactive oxygen species, and neutrophil extracellular traps (NETs), which are crucial to combat pathogens, but in large amounts are harmful to the host tissue. 5 Survival depends on the severity of lung injury, the extension of damage to other organs, comorbidities of the infected patient, and the quality of medical care. 6 SARS-CoV-2, via its surface protein Spike, uses angiotensinconverting enzyme-2 (ACE2) for host entry via airway epithelial cells. 7 ACE2 is an enzyme highly expressed on the apical side of polarized alveolar epithelial cells and lung endothelial cells that cleaves the peptide hormone angiotensin-I into Ang1-9 and Ang1-7, peptides known to protect against epithelial and endothelial hyperpermeability and excessive inflammation. 8 Genetic deletion of ACE2 worsens lung inflammation, while Ang1-7 administration improves it. 9 Coronavirus infection causes down-regulation of ACE2 by activating enzymes known to cleave ACE2 10 including a disintegrase and metalloprotease 17 (ADAM17). 11, 12 ADAM17 sheds the extracellular domain of ACE2 from the surface of lung epithelial cells thus reducing the protective ACE2-dependent signaling leading to a detrimental feedback loop of exacerbated lung inflammation. Moreover, ADAM17 produces the active form of the proinflammatory cytokine TNF-α and is critical for proinflammatory cytokine secretion thus contributing to the cytokine storm, another feature of severe COVID-19 that triggers excessive neutrophil recruitment. [13] [14] [15] Although it is well known that ADAM17 gets activated after SARS-CoV infection, 12 cleaves ACE2, and is therefore likely involved in COVID-19 pathogenesis, 16 the role of ADAM17 in the development of severe COVID-19 has not been experimentally analyzed.

Pharmacologic therapy of critically ill patients relies on inhibiting viral replication and inflammatory responses. 17 Although the development of vaccines has been astonishingly fast and much progress has been made with vaccinations worldwide, specific treatments to prevent the development of severe COVID-19 in infected individuals are still desperately needed for those that do not wish to or cannot be vaccinated, or those that get infected despite being vaccinated.

We hypothesized that pharmacologic inhibition of ADAM17 protects against acute lung injury (ALI) by preventing excessive cytokine production and neutrophil recruitment. We show that intraperitoneal or intranasal administration of the ADAM17/MMP inhibitors apratastat and TMI-1 significantly reduces proinflammatory cytokine production and leukocyte recruitment to the lungs and thus improves lung histology. Our data suggest that inhibition of ADAM17/MMP is a viable strategy to prevent the development of severe COVID-19 and to reduce the requirement for critical care and COVID-19 death toll.

Pathogen-free 8-12 weeks old C57BL/6 male mice were obtained from the animal facility at CINVESTAV. All protocols have been approved by the institutional animal care and use committee of CINVESTAV.

The recombinant receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein (RBD-S) with amino and carboxy deletions (RDB-NTCT) was purified from Escherichia coli SoluBL21 (DE3) (Genlantis) cells transformed with pRSET-RDB-NTCT. Briefly, cells were grown in 20 ml LB broth supplemented with ampicillin (100 μg/ml) at 37 • C for 12 h at 150 rpm. This 20 ml of culture was added into 500 ml of 2xYT broth (tryptone16 g/L, yeast extract 10 g/L, and sodium chloride 5 g/L) and ampicillin (100 μg/ml), incubated at 37 • C under constant shaking at 200 rpm until reaching an OD 600 of 0.8. Expression of the protein was induced by adding 500 ml of 2xYT broth with 2 mM isopropyl β-D-galactopyranoside and 2 mM MgSO 4 (to reach a final volume of 1 L of culture containing 1 mM IPTG and 1 mM MgSO 4 ). The bacteria were incubated at 16 • C for 16 h and harvested by centrifugation at 2500 × g for 30 min at 4 • C. The bacterial pellet was resuspended in 20 ml of lysis buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM PMFS, 1 mM benzamidine, and 1 mM DTT) and sonicated in an ice bath using an Ultrasonic Homogenizer (500-Watt Cold Palmer, USA) for 4 min.

The cell lysate was centrifuged at 24,000 × g for 20 min at 4 • C. The purification of the RBD-S domain from inclusion bodies was performed as described previously 18 with the following modifications. To ensure removal of remnant endotoxins, inclusion bodies were washed 4 times with endotoxin-free wash-buffer (20 mM Tris-HCl pH 8, NaCl 100 mM, 2%Triton X-100, and 1 M urea). After each wash, the samples were centrifuged and the pellet resuspended in wash buffer so that each wash step resulted in a 1000× dilution of contaminants present in the inclusion bodies after isolation from the bacteria. The detergent in the wash buffer ensured that membranal endotoxins were washed off. The insoluble fraction was homogenized using an ULTRA-TURRAX 

This COVID-19-related preclinical model of lung inflammation is based on a recently published protocol with the exception that we here used the RBD domain of the SARS-CoV-2 Spike protein instead of the entire extracellular domain. 19 Mice were anesthetized by intraperitoneal injection of 200 mg/kg ketamine (Anesket, PISA, Mexico City) and 10 mg/kg xylazine (Procin, PISA, Mexico City). The trachea was surgically exposed and a sterile 31G needle was carefully inserted.

A combination of 10 mg/kg poly-I:C (Invivogen, San Diego, CA, USA) and 15 μg of the recombinant RBD-S in 60 μl endotoxin-free physiologic saline was instilled followed by 100 μl of air to fill the lungs.

Sham-operated animals received physiologic saline alone as control.

The wounds were sutured, and the mice were left to recover in cages. The ADAM17 inhibitors apratastat and TMI-1 were purchased from Sigma-Aldrich-Merck (Toluca, Mexico). However, both apratastat and TMI-1 can also inhibit other MMP; thus, we refer to them as ADAM17/MMP inhibitors. Apratastat and TMI-1 were administered intraperitoneally at 10 mg/kg. 20, 21 Apratastat was administered twice (4 and 16 h after surgery) and TMI-1 was administered once (4 h after surgery) for the 24 h time point; for the 4 h time point, inhibitors were administered after 1 h; and for the 48 h time point, additionally after 32 h. DMSO was administered as vehicle control. Apratastat was also administered intranasally at 10 mg/kg; but, unfortunately, TMI-1 was no longer available to us when we started these experiments. Four hours, 24 h, or 48 h after induction of lung inflammation, blood samples (cardiac puncture), lung tissue, and bronchoalveolar lavage fluid (BALF)

were obtained for analysis of inflammation as described below.

After obtaining blood by cardiac puncture, 20 ml of PBS was transcardially perfused until the lungs turned white. The right lung was extracted and fixed in 4% formalin. Fixed lung specimens were dehydrated and embedded in paraffin. Four micrometers of cross-sections were stained with H&E according to standard protocols. A pathologist analyzed the samples for the degree of inflammation in a blinded fashion and determined the histopathologic scores as previously published. 22

Twenty-four hours after induction of lung inflammation, mice were euthanized by anesthesia overdose and bronchoalveolar lavage was performed as described before. 23 Briefly, the rib cage was removed, and a plastic cannula was inserted into the trachea and lungs were flushed 3 times with 0.8 ml PBS. This procedure was repeated 4 times.

Pooled BALF was analyzed by flow cytometry as described below.

Left lungs were put in 2 ml microtubes with 1 ml prewarmed PBS containing 200 units of collagenase (Sigma; C9891) and 0.9 mM of calcium and magnesium. Tissue was cut into pieces using sharp scissors. 

Cells from blood, BALF, and lung suspension were blocked for 15 min identified as CD45 high /side scatter low . Data were acquired using a FACS Canto II and analyzed using FlowJo V10 software.

Total RNA was isolated and purified from lung tissues using Trizol Reagent (Invitrogen, CA, USA). cDNA was obtained by reversetranscribing the purified RNA using the first stand cDNA synthesis kit (ThermoFisher, MA, USA). The following primer pairs were used: β- 

The levels of serum TNF-α were determined using the LEGEND MAX Mouse TNF-α ELISA kit (Biolegend, CA, USA) according to the manufacturert's instructions.

Data were analyzed using GraphPad Prism Version 6.0. The Shapiro-Wilk normality test was used to prove normal distribution of data.

One-way ANOVA followed by Dunnett post-hoc test was then used for multigroup comparisons. p values < 0.05 were considered statistically significant.

To investigate potential beneficial effects of ADAM17 inhibition on COVID-19-related lung inflammation, we employed a preclinical mouse model, in which we instilled a combination of the TLR-3 ligand poly(I:C) and the recombinant RBD-S into mouse lungs to mimic SARS-CoV-2 infection (Figure 1(A) ). This preclinical COVID-19 model is based on recently published protocols, 19, 22 with the simplification that we used the Spike RBD-domain instead of the whole extracellular domain. To demonstrate that our model is not just an ALI, we compared signs of inflammation such as leukocyte recruitment into lung tissue and BALF when applying poly(I:C) alone versus poly(I:C) combined with RBD-S (Figures 1(B)-1(J) ). We found that the combination of poly(I:C)/RBD-S induced much stronger recruitment of neutrophils into lung tissue (Figure 1(B) ) and BALF (Figure 1 (E)) compared with poly(I:C) alone. We also observed more macrophages in both lungs (Figure 1(C)) and BALF (Figure 1(F) ). However, we did not observe altered numbers of T cells in lung tissue (Figure 1 

Massive neutrophil infiltration is a key feature of COVID-19associated lung injury. 26, 27 Because the histology indicated reduced leukocyte presence in lungs after ADAM17/MMP inhibition, we quantified leukocyte populations by flow cytometry. As expected, the number of neutrophils was strongly increased 24 h after instillation of poly(I:C)/RBD-S, and both apratastat and TMI-1 significantly reduced the number of neutrophils in the lungs (Figure 3(A) ). Also, the number . The poly(I:C)/RBD-S + vehicle group shows major inflammatory changes such as alveolar wall/septa thickening (bold black arrow) and alveolar space closing and fibrosis (arrowhead), leukocyte infiltration (+), and vascular congestion (star). The lung tissues of poly(I:C)/RBD-S + apratastat and + TMI groups clearly show less inflammatory damage and overall a better-preserved tissue morphology. (B) Histologic scores of the lung tissues based on the extent of inflammatory changes with 0 = absence, 1 = low, 2 = moderate, 3 = high. Data are shown as mean ± SEM of images from at least 4 independent tissue preparations. *p < 0.05, ****p < 0.0001 of lung macrophages was much higher in inflamed lungs compared with controls, and again both apratastat and TMI-1 strongly reduced macrophage numbers in the lungs (Figure 3(B) ). By contrast, numbers of T cells were significantly reduced in inflamed lungs, and T cell numbers increased after treatment with either apratastat or TMI-1 ( Figure 3(C) ).

Next, we analyzed leukocyte populations in the BALF, that is, those leukocytes that transmigrated the epithelium to reach the alveolar lumen. 28 We found similar results for neutrophils (Figure 3 

Increased NLR is a well-established risk factor for severe COVID-19. 26 Given the changes in leukocyte numbers in the lung, we next analyzed neutrophil and T cell numbers in the blood. We found that poly(I:C)/RBD-S-induced lung inflammation caused neutrophilia that was clearly ameliorated by ADAM17/MMP inhibition (Figure 4(A) ).

Also, we observed significantly reduced T cell numbers in response to poly(I:C)/RBD-S instillation; however, T cell numbers were not changed after ADAM17/MMP inhibition (Figure 4(B) ). The reduced neutrophil numbers in combination with overall unaltered lymphocyte numbers resulted in a significant reduction of the NLR (Figure 4(C) ), which likely contributes to the protective effect observed with ADAM17/MMP inhibition. 

Another classical feature of severe COVID-19 is the cytokine storm, which in turn leads to endothelial activation, massive leukocyte recruitment and leukocyte hyperactivation. 27 ADAM17 is the enzyme responsible for releasing the active form of TNF-α. 29 Thus, we expected ADAM17 inhibition to also impact cytokine expression and endothelial activation, which in consequence is the basis for To better understand the timing of the inflammatory response and treatments in our model, we analyzed leukocyte recruitment and cytokine production also after 4 and 48h ( Figures S1 and S2 ).

After 4 h, we only found weak increases in leukocyte recruitment in response to poly(I:C)/RBD-S ( Figure S1 ), although increased cytokine and adhesion molecule production was already detectable ( Figure   S2 ). However, hardly any significant effect on leukocyte recruitment was observed with the ADAM17/MMP inhibitors at this time. After 48 h, the differences in leukocyte numbers in the lung tissue were not as pronounced as after 24 h. However, we observed significantly higher leukocyte numbers in the BALF ( Figure S1 ). Moreover, after 48 h, we only detected reduced production of TNF-α and increased production of IL-10, but no significant differences of other cytokines and adhesion molecules ( Figure S2 ), suggesting that inflammation resolution has started after 48 h under these conditions.

The effects of the ADAM17/MMP inhibitors on NLR was strongest after 24 h ( Figure S1 ). Overall, these data suggest that in our model strong inflammation in response to poly(I:C)/RBD-S and most signif-icant protective effects of ADAM17/MMP inhibitors can be studied after 24 h.

Intranasal administration of ADAM17/MMP inhibitors also prevents excessive leukocyte recruitment to the lungs in response to poly(I:C)/RBD-S All the data described above were obtained after intraperitoneal administration of the ADAM17/MMP inhibitors. As this is not a desirable route of applying drugs in human patients, we wanted to know whether local application of apratastat via the intranasal route would show similar effects. Importantly, we observed similar results with respect to the leukocyte populations in lung tissue and BALF. Lung neutrophils during poly(I:C)/RBD-S-induced lung inflammation were reduced almost to control levels with ADAM17/MMP inhibition (Figure 6(A) ); lung macrophages were significantly reduced although not to control levels ( Figure 6(B) ); and lung T cell numbers were increased by apratastat (Figure 6 

Albeit herculean research efforts worldwide to understand COVID- (8-10 weeks) . It will be interesting to see whether older or obese animals will develop a more severe disease, because, if so, this model will also be appropriate to study the molecular differences in high-risk groups.

ACE2 is not just the receptor for SARS-CoV and SARS-CoV-2, 7,34 but it is also a critical enzyme regulating the production of angiotensinogenic peptides, inflammation, and vascular and epithelial permeability. 8 Thus, correct regulation of its enzymatic functions is of utmost importance for correct lung functionality, and loss of ACE2 by enzymatic cleavage is detrimental for lung functions. 29 known as TNF-α-converting enzyme (TACE), is responsible for producing the active form of TNF-α. 11 We showed that TNF-α production is indeed significantly reduced after ADAM17 inhibition in our COVID-19 model. Reduced TNF-α levels in turn may lead to reduced synthesis of other proinflammatory cytokines due to less NF-κB activation. This is likely an important mechanism responsible for the protective effect of ADAM17 inhibition against COVID-19-associated lung injury. Whether ADAM17 directly affects the production of other proinflammatory cytokines and chemokines or whether this an indirect effect of altered TNF-α production needs to be investigated in the future.

ADAM17 is also expressed in neutrophils, where it gets activated in response to integrin activation leading to cleavage of L-selectin, enhanced neutrophil effector functions and bacterial clearance in the lung. 36 It will be important to analyze whether such mechanisms, at least to some degree, also play a role in viral clearance in mild to moderate COVID-19. However, in the context of severe COVID-19, it is rather important to dampen neutrophil hyperactivation in response to the cytokine storm because excessive uncontrolled neutrophil effector functions including release of proteases, reactive oxygen species, and NETs contribute to tissue damage as those substances do not distinguish between host and pathogens. 5 On the other hand, lack of ADAM17 in neutrophils 37, 38 or ADAM17 inhibition in the context of sepsis 15 has been shown to accelerate neutrophil recruitment. We observed here significantly reduced neutrophil presence in lung tissue and BALF and consequently an improved NLR. However, it is still unclear whether this inhibitory effect is due to ADAM17 inhibition in neutrophils, endothelial cells, epithelial cells, or all cell types. It is also important to consider that neutrophil recruitment into the lung follows molecular steps different from those in other tissues 39 and that recruitment to different lung compartments in different COVID-19 stages is also governed by distinct mechanisms. 40 Thus, more research is required to unravel the mechanisms underlying the altered neutrophil recruitment patterns in our model of COVID-19-related lung inflammation.

Apratastat (TMI-005) and TMI-1 are structurally related orally bioavailable ADAM17/MMP inhibitors of the thiomorpholine sulfonamide hydroxymate family. 21 These compounds are specific for ADAM17 and barely inhibit the related ADAM10. 41 However, they also inhibit other MMP to a certain extent. Thus, we cannot exclude that some of the observed effects are a result of partial MMP inhibition. Especially TMI-1 has been reported to inhibit MMP-1, −2, and −13 at concentrations similar to those needed to inhibit ADAM17. 21 Thus, it is tempting to speculate that, in the cases where we observed stronger effects of TMI-1 compared with apratastat, for example, in the histologic score (Figure 2(B) ), the reduction of IL-1 and IL-6 ( Both apratastat and TMI-1 have been shown to inhibit TNF-α secretion in preclinical models of rheumatoid arthritis (RA); and apratastat (but not TMI-1) has been tested in clinical trials to treat RA patients. 21, 42 However, although effective in reducing TNF-α levels, apratastat did not improve the clinical manifestations in RA patients so that the study was terminated. 43 Despite this disappointing clinical result, apratastat and TMI-1 could still be useful for the treatment of COVID-19 patients because in this context we observed not only a protective effect on TNF-α production, but also on neutrophil recruitment and NLR, all critical features of severe COVID-19 pathogenesis. Moreover, pharmacodynamics and pharmacokinetics data from clinical studies showed that at least apratastat is well tolerated and bioavailable in humans 44 so that it will be feasible to test apratastat in clinical trials for efficacy in inhibiting severe COVID-19 development in SARS-CoV-2infected patients. Unfortunately, pharmacodynamics and pharmacokinetics data for TMI-1 in humans are not available.

In summary, we provide experimental evidence that ADAM17/MMP inhibition by apratastat and TMI-1 protects against lung inflammation in a novel, simplified mouse model of COVID-19-associated lung injury. ADAM17/MMP inhibitors reduced the cytokine storm and excessive neutrophil recruitment to the lung while improving NLR. Thus, we propose to use these drugs in clinical trials to test their efficacy in COVID-19 patients.

This work was supported by funds from the Agencia Mexicana de Cooperación Internacional para el Desarrollo (AMEXCID) of the Secretaría de Relaciones Exteriores (SRE) (Projects AMEXCID_2020-4 to

acknowledges funding from Consejo Nacional de Ciencia y Tecnología (CONACYT; CB-2016-284292; and PRONAII Leukemia grant 302978 of the National Strategic Health Program

:1), and Gobierno del Estado de Hidalgo (Proyectos Sincrotrón 20201120 and 20201039). S. V. R. received a postdoctoral fellowship from CONACYT

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Neutrophil-to-lymphocyte ratio and outcomes in Louisiana COVID-19 patients

A shift towards an immature myeloid profile in peripheral blood of critically Ill COVID-19 patients

Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19

COVID-19 pneumonia, and acute respiratory distress syndrome

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Angiotensin-converting enzyme 2: sARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2

Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

The shedding protease ADAM17: physiology and pathophysiology

Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS

Immunopathological roles of neutrophils in virus infection and COVID-19. Shock

COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps

Ectodomain shedding by ADAM17: its role in neutrophil recruitment and the impairment of this process during sepsis

ADAM17 inhibition may exert a protective effect on COVID-19

Race to find COVID-19 treatments accelerates

Production of recombinant TSA-1 and evaluation of its potential for the immunotherapeutic control of Trypanosoma cruzi infection in mice

Cytokine signature induced by SARS-CoV-2 spike protein in a mouse model

ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice

Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecar boxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis

TLR3 regulated Poly(I:c)-induced neutrophil extracellular traps and acute lung injury partly through p38 MAP kinase

Murine bronchoalveolar lavage

Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology-a systematic review

Postmortem examination of patients with COVID-19

Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis

Hussman JP Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19

How leukocytes cross the vascular endothelium

Comparative analysis reveals the speciesspecific genetic determinants of ACE2 required for SARS-CoV-2 entry

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

Modulation of TNFalpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry

L-selectin shedding affects bacterial clearance in the lung: a new regulatory pathway for integrin outside-in signaling

In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli-mediated peritonitis

Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites

Neutrophil recruitment: from model systems to tissue-specific patterns

Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19

Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol esterinducible shedding of cell surface molecules

Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis

Pharmacokineticpharmacodynamic modeling of apratastat: a population-based approach

ADAM17/MMP inhibition prevents neutrophilia and lung injury in a mouse model of COVID-19